Acid suppressive agents and risk of Mycobacterium Tuberculosis: Case-control study

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Hsu, Wen Hung ^a,b   Kuo, Chao Hung ^a,b   Wang, Sophie S W ^a   Lu, Chien Yu ^a,b   Liu, Chung Jung ^a   Chuah, Seng Kee ^c   Kuo, Fu Chen ^d   Chen, Yen Hsu ^a   Huang, Yaw Bin ^e   Hou, Ming Feng ^a   Wu, Deng Chyang ^a,b,f   Hu, Huang Ming ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Histamine2 receptor antagonist; Mycobacterium Tuberculosis; National health insurance database; Proton pump inhibitor; Taiwan

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; ETHAMBUTOL; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISONIAZID; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; PYRAZINAMIDE; RABEPRAZOLE; RANITIDINE; RIFAMPICIN; ANTIULCER AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYCOBACTERIUM TUBERCULOSIS; NATIONAL HEALTH INSURANCE; PEPTIC ULCER; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PREVALENCE; PRIMARY TUMOR; REFLUX ESOPHAGITIS; RISK ASSESSMENT; SOCIAL STATUS; TAIWAN; TREATMENT DURATION; TUBERCULOSIS; AGED; EPIDEMIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK; RISK FACTOR; TIME;

ADULT; AGED; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME FACTORS; TUBERCULOSIS;

EID: 84901264059     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-91     Document Type: Article

References (33)

1. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000, 95(11):3118-3122.
2. Noguerado Asensio A, Rodriguez Barrientos R, Zelaya Castro P, Sanchez Sempere A, Antuna Blanco F, Lutz Garcia E, Quintana de la Cruz R, Estelles Piera F, Alcazar MS. Use of acid-suppressive medications in hospitalized patients. An Med Interna 2002, 19(11):557-560.
3. Strid H, Simren M, Bjornsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrol Dial Transplant 2003, 18(3):570-575. 10.1093/ndt/18.3.570, 12584281.
4. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294(23):2989-2995. 10.1001/jama.294.23.2989, 16414946.
5. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007, 5(12):1418-1423. 10.1016/j.cgh.2007.09.010, 18054750.
6. Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, Saeian K. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009, 104(5):1130-1134. 10.1038/ajg.2009.80, 19337238.
7. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292(16):1955-1960. 10.1001/jama.292.16.1955, 15507580.
8. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009, 301(20):2120-2128. 10.1001/jama.2009.722, 19470989.
9. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167(9):950-955. 10.1001/archinte.167.9.950, 17502537.
10. Chiang CY, Kim SJ. Increasing drug resistance of Mycobacterium tuberculosis in a medical center--what about in Taiwan overall?. J Formos Med Assoc 2009, 108(1):1-3. 10.1016/S0929-6646(09)60025-5, 19181601.
11. Hsueh PR, Liu YC, So J, Liu CY, Yang PC, Luh KT. Mycobacterium tuberculosis in Taiwan. J Infect 2006, 52(2):77-85. 10.1016/j.jinf.2005.08.008, 16216328.
12. WHO global tuberculosis control report Summary. Cent Eur J Public Health 2010, 18(4):237. WHO global tuberculosis control report.
13. Sethi S, Mewara A, Dhatwalia SK, Singh H, Yadav R, Singh K, Gupta D, Wanchu A, Sharma M. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. BMC Infect Dis 2013, 13:137. 10.1186/1471-2334-13-137, 3610146, 23497169.
14. Thorn PA, Brookes VS, Waterhouse JA. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. Br Med J 1956, 1(4967):603-608. 10.1136/bmj.1.4967.603, 1979202, 13293399.
15. Steiger Z, Nickel WO, Shannon GJ, Nedwicki EG, Higgins RF. Pulmonary tuberculosis after gastric resection. Am J Surg 1976, 131(6):668-671. 10.1016/0002-9610(76)90174-4, 937642.
16. Kolappan C, Gopi PG, Subramani R, Narayanan PR. Selected biological and behavioural risk factors associated with pulmonary tuberculosis. Int J Tuberc Lung Dis 2007, 11(9):999-1003.
17. Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am 2010, 24(3):751-768. 10.1016/j.idc.2010.04.011, 20674802.
18. Vakil N. Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009, 104(Suppl 2):S17-20.
19. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008, 149(6):391-398. 10.7326/0003-4819-149-6-200809160-00005, 18794558.
20. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009, 18(4):269-275. 10.1002/pds.1715, 19235776.
21. Rodriguez LA, Ruigomez A, Wallander MA, Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009, 20(6):800-806. 10.1097/EDE.0b013e3181b5f27d, 19797970.
22. Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010, 123:47-53. 10.1016/j.amjmed.2009.05.032, 20102991.
23. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010, 31(11):1165-1177. 10.1111/j.1365-2036.2010.04284.x, 20222914.
24. Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, Cheng SH, Wang JT, Liu YC, Cheng YW, Chen ST, Fung CP, Chuang YC, Cheng HP, Lu DC, Liu CJ, Huang IW, Hung CL, Hsiao CF, Ho M. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005, 99(9):1079-1086. 10.1016/j.rmed.2005.02.026, 16085210.
25. Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med 2005, 26(1):47-55. 10.1016/j.ccm.2004.10.016, 15802165.
26. Nava-Aguilera E, Andersson N, Harris E, Mitchell S, Hamel C, Shea B, Lopez-Vidal Y, Villegas-Arrizon A, Morales-Perez A. Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2009, 13(1):17-26.
27. Chin DP, Crane CM, Diul MY, Sun SJ, Agraz R, Taylor S, Desmond E, Wise F. Spread of Mycobacterium tuberculosis in a community implementing recommended elements of tuberculosis control. JAMA 2000, 283(22):2968-2974. 10.1001/jama.283.22.2968, 10865275.
28. Boman K. Tuberculosis occurring after gastrectomy. Acta Chir Scand 1956, 110(6):451-457.
29. Yokoyama T, Sato R, Rikimaru T, Hirai R, Aizawa H. Tuberculosis associated with gastrectomy. J Infect Chemother 2004, 10(5):299-302. 10.1007/s10156-004-0334-2, 16163466.
30. Huang SF, Li CP, Feng JY, Chao Y, Su WJ. Increased risk of tuberculosis after gastrectomy and chemotherapy in gastric cancer: a 7-year cohort study. Gastric Cancer 2011, 14(3):257-265. 10.1007/s10120-011-0037-1, 21503597.
31. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009, 104(Suppl 2):S5-9.
32. Taiwan tuberculosis control report. 2009, [http://www.cdc.gov.tw/].
33. Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1997-2000. Int J Clin Pharmacol Ther 2003, 41(5):207-212. 10.5414/CPP41207, 12776811.